|
Back to Home » July 2016 News » Biohaven Reports Dosing of First Subject in Pharmacokinetic and Safety Trial of BHV-4157 |
Biohaven Reports Dosing of First Subject in Pharmacokinetic and Safety Trial of BHV-4157 |
July 20, 2016
NEW HAVEN, CT--(Marketwired - July 20, 2016) - Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") reported today that the Company has begun dosing subjects in its first clinical trial to evaluate the safety and pharmacokinetics of BHV-4157. Biohaven recently received clearance from the FDA on its IND and permission to begin dosing in humans.
Source URL: http://www.marketwired.com/mw/release.do?id=2143791&sourceType=3
|
|
|
|